Idera to Present at the Piper Jaffray Healthcare Conference
Piper Jaffray Healthcare Conference 2012
CAMBRIDGE, Mass. -- November 26, 2012
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company developing
Toll-like receptor targeted product candidates for the treatment of autoimmune
diseases and as vaccine adjuvants, today announced that its management will
present a company overview at the 24th Annual Piper Jaffray Healthcare
Conference in New York, NY. The presentation will take place on Wednesday,
November 28, 2012 at 9:00 a.m. ET.
A live audio webcast of the presentation will be available in the Investor
section of Idera's website: www.iderapharma.com. An archived version will also
be available on the Company's website after the event for a limited time.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug
discovery platform to create immunomodulatory drug candidates and has a
clinical development program in autoimmune diseases. Additionally, Idera has a
collaboration with Merck & Co. for the use of TLR-targeted candidates as
vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. The
Company is also advancing its gene-silencing oligonucleotide (GSO) technology
for the purpose of inhibiting the expression of disease-promoting genes. For
more information, visit http://www.iderapharma.com.
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For
this purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking statements. There
are a number of important factors that could cause Idera's actual results to
differ materially from those indicated by such forward-looking statements,
including whether Idera’s cash resources will be sufficient to fund the
Company’s continuing operations and the further development of the Company’s
autoimmune disease program; whether results obtained in preclinical studies
and early clinical trials, such as the results from the preclinical studies
referred to in this release, will be indicative of results obtained in future
clinical trials; whether products based on Idera's technology will advance
into or through the clinical trial process on a timely basis or at all and
receive approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company's products
receive approval, they will be successfully distributed and marketed; whether
the Company will be able to license any of its TLR target candidates on a
timely basis or at all; whether the Company's collaboration with Merck & Co,
Inc., will be successful; whether the patents and patent applications owned or
licensed by the Company will protect the Company's technology and prevent
others from infringing it; and such other important factors as are set forth
under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2012 which important factors are incorporated
herein by reference. Idera disclaims any intention or obligation to update any
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
Press spacebar to pause and continue. Press esc to stop.